TY - JOUR
T1 - CVOT summit report 2024
T2 - new cardiovascular, kidney, and metabolic outcomes
AU - Schnell, Oliver
AU - Almandoz, Jaime
AU - Anderson, Lisa
AU - Barnard-Kelly, Katharine
AU - Battelino, Tadej
AU - Blüher, Matthias
AU - Busetto, Luca
AU - Catrinou, Doina
AU - Ceriello, Antonio
AU - Cos, Xavier
AU - Danne, Thomas
AU - Dayan, Colin M.
AU - Del Prato, Stefano
AU - Fernández-Fernández, Beatriz
AU - Fioretto, Paola
AU - Forst, Thomas
AU - Gavin, James R.
AU - Giorgino, Francesco
AU - Groop, Per Henrik
AU - Harsch, Igor A.
AU - Heerspink, Hiddo J. L.
AU - Heinemann, Lutz
AU - Ibrahim, Mahmoud
AU - Jadoul, Michel
AU - Jarvis, Sarah
AU - Ji, Linong
AU - Kanumilli, Naresh
AU - Kosiborod, Mikhail
AU - Landmesser, Ulf
AU - Macieira, Sofia
AU - Mankovsky, Boris
AU - Marx, Nikolaus
AU - Mathieu, Chantal
AU - McGowan, Barbara
AU - Milenkovic, Tatjana
AU - Moser, Othmar
AU - Müller-Wieland, Dirk
AU - Papanas, Nikolaos
AU - Patel, Dipesh C.
AU - Pfeiffer, Andreas F.H.
AU - Rahelić, Dario
AU - Rodbard, Helena W.
AU - Rydén, Lars
AU - Schaeffner, Elke
AU - Spearman, C. Wendy
AU - Stirban, Alin
AU - Tacke, Frank
AU - Topsever, Pinar
AU - Van Gaal, Luc
AU - Standl, Eberhard
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5–6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). These studies represent significant advances in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The congress also comprised sessions on novel and established therapies for managing HFpEF, CKD, and obesity; guidelines for managing CKD and metabolic dysfunction-associated steatotic liver disease (MASLD); organ crosstalk and the development of cardio-kidney-metabolic (CKM) syndrome; precision medicine and person-centered management of diabetes, obesity, cardiovascular disease (CVD) and CKD; early detection of type 1 diabetes (T1D) and strategies to delay its onset; continuous glucose monitoring (CGM) and automated insulin delivery (AID); cardiovascular autonomic neuropathy (CAN) and the diabetic heart; and the role of primary care in the early detection, prevention and management of CKM diseases. The contribution of environmental plastic pollution to CVD risk, the increasing understanding of the efficacy and safety of incretin therapies in the treatment of CKM diseases, and the latest updates on nutrition strategies for CKM management under incretin-based therapies were also topics of interest for a vast audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians, who actively engaged in online discussions. The 11th CVOT Summit will be held virtually on November 20–21, 2025 (http://www.cvot.org).
AB - The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5–6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). These studies represent significant advances in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The congress also comprised sessions on novel and established therapies for managing HFpEF, CKD, and obesity; guidelines for managing CKD and metabolic dysfunction-associated steatotic liver disease (MASLD); organ crosstalk and the development of cardio-kidney-metabolic (CKM) syndrome; precision medicine and person-centered management of diabetes, obesity, cardiovascular disease (CVD) and CKD; early detection of type 1 diabetes (T1D) and strategies to delay its onset; continuous glucose monitoring (CGM) and automated insulin delivery (AID); cardiovascular autonomic neuropathy (CAN) and the diabetic heart; and the role of primary care in the early detection, prevention and management of CKM diseases. The contribution of environmental plastic pollution to CVD risk, the increasing understanding of the efficacy and safety of incretin therapies in the treatment of CKM diseases, and the latest updates on nutrition strategies for CKM management under incretin-based therapies were also topics of interest for a vast audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians, who actively engaged in online discussions. The 11th CVOT Summit will be held virtually on November 20–21, 2025 (http://www.cvot.org).
KW - Cardiovascular disease
KW - CGM
KW - Chronic kidney disease
KW - CKM
KW - Diabetes
KW - Finerenone
KW - GLP-1 RA
KW - Guidelines
KW - Heart failure
KW - MASLD
KW - Obesity
KW - SGLT2 inhibitor
KW - Tirzepatide
UR - https://www.scopus.com/pages/publications/105004355871
U2 - 10.1186/s12933-025-02700-0
DO - 10.1186/s12933-025-02700-0
M3 - Comment/debate
C2 - 40316962
AN - SCOPUS:105004355871
SN - 1475-2840
VL - 24
JO - Cardiovascular diabetology
JF - Cardiovascular diabetology
IS - 1
M1 - 187
ER -
